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BehçetDisease (BD) is a systemic vasculitis characterized by recurrent oral and genital ulcers and uveitis, arthritis,
and involvement of the gastrointestinal tract, central nervous system and blood vessels. The aneurysms of the
pulmonary arteries, with or without thrombosis, are typical manifestation of BD. We report a case with BD,
pulmonary arterial aneurysms(PAA) and in situ thrombosis. We aimed to show the effectiveness of
immunosuppressive treatment on in situ thrombosis in a case with PAA and BD.
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Behçet’s disease (BD) was firstly described by Hulusi
Behçet in 1937. It is a systemic vasculitis characterized
by recurrent oral and genital ulcers and uveitis, arthritis,
and involvement of the gastrointestinal tract, central
nervous system and blood vessels [1]. Pulmonary artery
aneurysm (PAA) is reported in 1.5 % of adults with BD.
Thrombosis of the pulmonary arteries in BD is usually
an in situ thrombosis [2]. Some articles reported that
immunosuppressive therapy is essential, and anticoagu-
lant therapy might not be required for the treatment of
venous disease associated with BD [3]. We aimed to
show the effectiveness of immunosuppressive treatment
on in situ thrombosis in a case with PAA and BD.Case presentation
A 25-year-old,non-smoker turkish man was admitted to
hospital with complaints of chest pain and cough. The
chest radiography showed well-defined, rounded opaci-
ties on the left hemithorax (Figure 1). The thorax CT
and MRI revealed vascular aneurysms with in situ
thrombosis on the left pulmonary artery (Figure 2 and
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reproduction in any medium, provided the oraphthous ulcers. The skin pathergy test was positive
(Figure 4). BD was diagnosed based on these findings.
The treatment was started with intravenous pulse
methylprednisolone (250 mg per day for 3 days) and
monthly 1,000 mg cyclophosphamide, and followed by
1 mg/kg per day of methylprednisolone orally, colchium
and intravenous pulse of 1,000 mg cyclophosphamide-
monthly. Thorax CT was repeated after 2 months of
treatment. It showed that PAAs were reduced and in situ
thrombosis in PAAs was completely resolved with im-
munosuppressive treatment (Figure 5). The approval of
patient and of institution were taken to use their records
for our study.Conclusions
After the aorta, the pulmonary arteries are the most
common site of arterial involvement among the pulmon-
ary manifestations in patients with BD [4]. PAAs asso-
ciated with BD tend to be multiple, as seen in our
patient. The hemoptysis is the commonest symptom of
PAA in BD, and one of the leading causes of death [5].
In the present case there was no hemoptysis. The aneur-
ysms of the pulmonary arteries, with or without throm-
bosis, are typical manifestation of BD [6]. Tunacı et al.
reported mural thrombotic changes during regression of
PAAs [7]. The underlying pathophysiologic process is in-
flammation of the vasa vasorum of the tunica media,
which causes destruction of the elastic fibers of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chest radiography is showing the well-shaped, round
hilar opacities on left hemithorax.
Figure 2 Thorax CT scans are showing the aneurysmatic dilatations a
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the vessel wall is caused by inflammation and infiltration
by lymphocytes, plasma cells and neutrophils. Throm-
bosis of the pulmonary arteries in BD is usually an in
situ thrombosis [2,8]. Because the main problem is the
inflammation of pulmonary arteries, the main stay of
treatment should be the anti-inflammatory and im-
munosuppressive agents in patients with PAA and BD.
A combination of cyclophosphamide and methylpredni-
solone is used most frequently in patients with PAA [9].
We know that anticoagulant therapy could increase the
risk of aneurysmal rupture and anticoagulant drugs
might be unnecessary in BD [5]. Mehta et al. reported a
case with in situ thrombosis with BD [10]. They reported
the patient had remained clinically stable with no further
episodes of hemoptysis with immunosuppressive treat-
ment including dexamethasone and cyclophosphamide
[10]. However, there was no radiologically demonstrated
efficacy of immunosuppressive treatment on in sitund in situ thrombosis in the left pulmonary artery (white arrows).
Figure 3 The thoracic MRI is showing the well-shaped, round
hilar opacities on left hemithorax.
Figure 5 Thorax CT scans showing that in situ thrombosis in
PAAs was completely resolved with immunsuppressive
treatment (white arrows).
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strate the effectiveness of immunosuppressive treatment
on in situ thrombosis with PAA in a patient with BD.
Contrast-enhanced thorax CT revealed the in situ
thrombosis on the wall of PAAs. After the immunosup-
pressive treatment the in situ thrombosis was completely
resolved and PAAs were reduced.
In conclusion, inflammation in pulmonary arteries is
causing in situ thrombosis and it contributes to the
development of PAAs in patients with BD. The anti-
inflammatory and immunosuppressive drugs are essen-
tial for the treatment of in situ thrombosis and PAAs in
patients with BD.Figure 4 The positive pathergy test is seen with pustular lesion
on injection area of body (black arrows).Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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